KBC Group
IONS icon

KBC Group’s Ionis Pharmaceuticals IONS Stock Holding History

KBC Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
30,213
+21,161
+234% +$1.67M 0.01% 635
2025
Q4 		$716K Buy
9,052
+4,353
+93% +$328K ﹤0.01% 692
2025
Q3 		$307K Hold
4,699
– – ﹤0.01% 777
2025
Q2 		$186K Sell
4,699
-1,816
-28% -$59.4K ﹤0.01% 893
2025
Q1 		$197K Buy
6,515
+31
+0.5% +$1.01K ﹤0.01% 1078
2024
Q4 		$227K Buy
6,484
+2,676
+70% +$100K ﹤0.01% 1060
2024
Q3 		$153K Buy
3,808
+419
+12% +$19.5K ﹤0.01% 1044
2024
Q2 		$162K Buy
3,389
+244
+8% +$10K ﹤0.01% 933
2024
Q1 		$136K Buy
3,145
+476
+18% +$22.7K ﹤0.01% 990
2023
Q4 		$135K Hold
2,669
– – ﹤0.01% 941
2023
Q3 		$121K Buy
2,669
+1,291
+94% +$53.3K ﹤0.01% 939
2023
Q2 		$57K Hold
1,378
– – ﹤0.01% 1337
2023
Q1 		$49K Hold
1,378
– – ﹤0.01% 1387
2022
Q4 		$52K Hold
1,378
– – ﹤0.01% 1377
2022
Q3 		$61K Hold
1,378
– – ﹤0.01% 1341
2022
Q2 		$51K Sell
1,378
-6,661
-83% -$251K ﹤0.01% 1413
2022
Q1 		$298K Buy
8,039
+22
+0.3% +$720 ﹤0.01% 946
2021
Q4 		$244K Sell
8,017
-895
-10% -$28.2K ﹤0.01% 1041
2021
Q3 		$299K Sell
8,912
-14,710
-62% -$554K ﹤0.01% 994
2021
Q2 		$942K Buy
23,622
+600
+3% +$23.5K ﹤0.01% 891
2021
Q1 		$1.04M Sell
23,022
-400
-2% -$22.3K ﹤0.01% 862
2020
Q4 		$7.28M Hold
23,422
– – ﹤0.01% 812
2020
Q3 		$1.11M Hold
23,422
– – ﹤0.01% 794
2020
Q2 		$1.38M Buy
23,422
+12,451
+113% +$693K ﹤0.01% 762
2020
Q1 		$519K Buy
10,971
+1,096
+11% +$61.1K ﹤0.01% 849
2019
Q4 		$597K Buy
9,875
+289
+3% +$17.2K ﹤0.01% 1057
2019
Q3 		$574K Buy
9,586
+8,791
+1,106% +$573K ﹤0.01% 1038
2019
Q2 		$51K Hold
795
– – ﹤0.01% 1355
2019
Q1 		$65K Hold
795
– – ﹤0.01% 1304
2018
Q4 		$43K Hold
795
– – ﹤0.01% 1227
2018
Q3 		$41K Sell
795
-1,869
-70% -$87.8K ﹤0.01% 1340
2018
Q2 		$111K Buy
2,664
+175
+7% +$7.76K ﹤0.01% 1184
2018
Q1 		$109K Buy
2,489
+620
+33% +$31.5K ﹤0.01% 1176
2017
Q4 		$94K Hold
1,869
– – ﹤0.01% 1184
2017
Q3 		$95K Hold
1,869
– – ﹤0.01% 1188
2017
Q2 		$95K Hold
1,869
– – ﹤0.01% 1184
2017
Q1 		$75K Hold
1,869
– – ﹤0.01% 1273
2016
Q4 		$89K Sell
1,869
-13,238
-88% -$524K ﹤0.01% 1262
2016
Q3 		$554K Buy
15,107
+6,378
+73% +$200K 0.01% 934
2016
Q2 		$203K Hold
8,729
– – ﹤0.01% 1088
2016
Q1 		$354K Sell
8,729
-1,381
-14% -$56.1K 0.01% 928
2015
Q4 		$626K Sell
10,110
-9,166
-48% -$495K 0.01% 740
2015
Q3 		$779K Sell
19,276
-7,126
-27% -$369K 0.02% 657
2015
Q2 		$1.52M Sell
26,402
-3,004
-10% -$191K 0.02% 628
2015
Q1 		$1.87M Buy
+29,406
New +$2M 0.02% 564

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's IONS Position: Q1 2026 in Review

KBC Group increased its Ionis Pharmaceuticals (IONS) stake by 234% in Q1 2026, buying an estimated $1.67M and bringing the position to 30,213 shares worth $2.27M. The position accounts for 0.01% of the portfolio, ranked #635.

KBC Group first reported a position in IONS in Q1 2015 and has held it in 45 quarters since. The position peaked at $7.28M in Q4 2020. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • KBC Group held 30,213 shares of Ionis Pharmaceuticals worth $2.27M as of Q1 2026.
  • KBC Group bought 21,161 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.67M.
  • Ionis Pharmaceuticals made up 0.01% of KBC Group's portfolio in Q1 2026, its #635 holding.
  • KBC Group first reported a position in Ionis Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
  • KBC Group's Ionis Pharmaceuticals position peaked at $7.28M in Q4 2020.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.